Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

This study is testing whether combining toripalimab (an immunotherapy drug) with radiation therapy can help control metastatic nasopharyngeal carcinoma (NPC, a cancer in the back of the nose) in patients with a limited number of metastatic sites (called oligometastatic disease). This combination is for patients who are not able or willing to receive chemotherapy. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed nasopharyngeal carcinoma that has spread to 5 or fewer sites in 2 or fewer organs - You have not received any prior treatment for metastatic NPC - You are not suitable for or do not wish to receive chemotherapy - You are in good health (ECOG score 0–1) with an expected survival of at least 6 months - Your blood counts and organ function meet required minimums **You may NOT be eligible if...** - You have an active autoimmune disease - You are on high-dose steroids or immune-suppressing medications - You have HIV, uncontrolled hepatitis B or C, or active tuberculosis - You have had a recent heart attack, severe heart failure, or stroke - You have interstitial lung disease or pulmonary fibrosis - You are pregnant or breastfeeding - You are currently in another clinical trial Talk to your doctor to see if this trial is right for you.